Peptide · Fact sheet

Tirzepatide

Also known as Mounjaro · Zepbound

Tirzepatide is FDA approved in specific prescription products and populations. Zepbound also has an FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity.

FDA approved for specific usesStrong human evidence for approved uses

What is Tirzepatide?

Tirzepatide is a manufactured medicine that activates two receptors involved in metabolic signaling: GIP and GLP-1.

Mounjaro and Zepbound contain the same active ingredient but have distinct FDA-labeled uses.

Benefits & claims

Interest centers on blood-sugar control, body-weight outcomes, and the obstructive-sleep-apnea indication.

It is also being studied for cardiovascular, kidney, and liver outcomes.

What the evidence supports

  • Trials supporting approved labels found benefits in their specified metabolic and sleep-apnea outcomes.
  • Additional outcome studies may clarify where benefits extend beyond current labels.
Research areas
  • Type 2 diabetes
  • Chronic weight management
  • Obstructive sleep apnea in adults with obesity
  • Cardiovascular and kidney outcomes
  • Metabolic liver disease
  • Additional cardiovascular, kidney, and liver outcomes
  • Other uses not listed in a current product label

Dosage & frequency

Product-specific label information

Mounjaro and Zepbound use weekly tirzepatide but have different indications, populations, and maintenance amounts.

Mounjaro

Adults and patients age ten years and older with type 2 diabetes

Amount
Start 2.5 mg for four weeks, then 5 mg; eligible 2.5 mg increases at least four weeks apart
Frequency
Once weekly
Route studied or labeled
Subcutaneous

Maximum 15 mg in adults; 10 mg in pediatric patients.

Zepbound: weight management

Adults meeting labeled weight-management criteria

Amount
Start 2.5 mg; maintenance 5, 10 or 15 mg after label escalation
Frequency
Once weekly
Route studied or labeled
Subcutaneous

2.5 mg is not maintenance; escalation steps require at least four weeks.

Zepbound: obstructive sleep apnea

Adults with obesity and moderate-to-severe obstructive sleep apnea

Amount
10 or 15 mg maintenance after label escalation
Frequency
Once weekly
Route studied or labeled
Subcutaneous

Indication-specific maintenance amounts.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Mounjaro is the diabetes product; Zepbound covers adult weight management and obstructive sleep apnea in adults with obesity.

Interactions & precautions

  • Insulin or insulin secretagogues increase hypoglycemia risk; delayed gastric emptying can affect oral medicines.
  • The labels warn that oral hormonal contraceptive effectiveness may be reduced after starting treatment or increasing the dose.

What is still unresolved

  • Different indications can require different maintenance choices.

Side effects & risks

  • Common effects include nausea, diarrhea, vomiting, constipation, abdominal discomfort, and other gastrointestinal symptoms.
  • Current labeling includes a boxed warning about thyroid C-cell tumors in rats and important contraindications.
  • Other labeled concerns include pancreatitis, gallbladder problems, kidney injury, hypoglycemia with certain medicines, and aspiration risk around anesthesia or deep sedation.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Strong human evidence for approved uses

Large randomized trials support approved indications. Results cannot be assumed to apply to unstudied populations, products, or claims.

Studies

What do the human studies show?

Selected research questions, not a complete inventory of indications or trials. Source checking is not independent clinical review. How we read the evidence.

Who took part, what was measured, and what the study found
Study and peopleQuestion and follow-upResult and limits
SURMOUNT-1

Adults with obesity or overweight plus a complication; diabetes excluded

2,539 participants (actual)

Randomized placebo-controlled trial; human

Tirzepatide versus Placebo

72 weeks

Primary: Percentage weight change and proportion reaching at least 5% reduction

Phase: Phase 3
Registry status: Not assessed
Registry results: Not assessed
Publication: published; peer reviewed

Active groups had greater mean weight reduction than placebo.

Cannot tell us: Weight change alone does not quantify cardiovascular-event or survival benefit; different active regimens are not pooled here.

Safety, uncertainty, and source details

Gastrointestinal events were most common; adverse events led to discontinuation in both active and placebo groups.

Limited to the studied population, formulation and follow-up.

Funding/conflicts: Supported by Eli Lilly; individual disclosures not fully extracted.

Source checked: 2026-09-18. Independent clinical review: not completed.

TRIUMPH-5

Adults with obesity

800 participants (estimated)

Randomized placebo-controlled trial; human

Retatrutide versus Tirzepatide

Primary weight endpoint: 80 weeks

Primary: Percentage body-weight change

Phase: Phase 3
Registry status: ACTIVE_NOT_RECRUITING
Registry results: Not posted
Publication: not assessed; not peer reviewed

Active, not recruiting; no registry results posted at the source check.

Cannot tell us: A registered head-to-head design is not a completed head-to-head result. Enrollment is estimated.

Safety, uncertainty, and source details

See primary paper; absence of a signal in this study does not establish general safety.

Limited to the studied population, formulation and follow-up.

Funding/conflicts: Sponsor: Eli Lilly and Company.

Source checked: 2026-09-18. Independent clinical review: not completed.

What these results can and cannot tell us

What did SURMOUNT-1 measure?

A placebo-controlled trial supports weight reduction in the studied adults. The OSA indication has its own label scope.

Limit: This weight trial alone does not establish cardiovascular-event prevention or prove every sleep-apnea indication.

Check the sources: SURMOUNT-1: tirzepatide and obesity (checked 2026-09-18) · FDA Zepbound prescribing information (checked 2026-09-18)

What is approved, and for whom?

United States records selected for the questions above; not a complete label or a worldwide approval inventory.

Zepbound: Weight management

Subcutaneous injection · Adults with obesity or overweight plus a weight-related condition

approved — Adjunct to reduced-calorie diet and increased physical activity.

Exact linked source and stated indication only; not an exhaustive regulatory search.

Read the original source · Source checked: 2026-09-18

Zepbound: Obstructive sleep apnea

Subcutaneous injection · Adults with obesity and moderate-to-severe obstructive sleep apnea

approved — Does not cover every cause or severity of sleep apnea.

Exact linked source and stated indication only; not an exhaustive regulatory search.

Read the original source · Source checked: 2026-09-18

Compare research questions · Submit a source-based correction

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 4 sourced accounts by reported effect.

Appetite: reported experiences

Mixed account · personal report

Little benefit with fatigue and brain fog

A reviewer described repeated fatigue, headache, brain fog and sleep difficulty over several weeks, with little glucose change, continued hunger and no weight loss.

Reported use in this account

Product
Mounjaro
Amount
Not specified clearly
Frequency
Weekly
Route
Injection; specific route not stated
Duration
Several weeks

This selected June 2023 review lacks clinical records and full treatment context. It cannot identify the cause of symptoms or establish nonresponse criteria.

Read the original account
Positive account · personal report

Less preoccupation with food

A person describing two weeks with tirzepatide reported less constant thinking about meals and more mental space for work.

Reported use in this account

Product
Product labeled tirzepatide
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Not specified clearly
Duration
Two weeks

This short, enthusiastic account is not a validated measure of cognition or a prediction of longer-term results. Selected public self-report; identity, product contents, other exposures and outcomes were not independently verified. It cannot establish causation or frequency.

Read the personal account

Approval status

Tirzepatide products are FDA approved for specific uses, including type 2 diabetes, chronic weight management, and—under the Zepbound label—moderate-to-severe obstructive sleep apnea in adults with obesity.

Approved uses

  • Improving blood sugar control in specified people with type 2 diabetes
  • Chronic weight management in specified adults
  • Moderate-to-severe obstructive sleep apnea in adults with obesity under the Zepbound label

FDA approved for product-specific uses

Mounjaro and Zepbound have FDA-approved indications, including diabetes, chronic weight management, and the Zepbound obstructive-sleep-apnea indication. The approval does not extend to every metabolic claim.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Outcomes for uses and populations not yet studied in large trials
  • Very long-term outcomes across increasingly broad populations
  • Whether every ongoing outcome trial will confirm early signals
  • Quality and safety of products marketed outside approved supply chains

Summary

Tirzepatide has strong evidence for specific approved uses, but brand, indication, eligibility, contraindications, and clinical oversight all matter.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA prescribing information: Mounjaro

    Official tirzepatide prescribing information for a type 2 diabetes product.

  2. fdaFDA prescribing information: Zepbound

    Official tirzepatide prescribing information for chronic weight management and obstructive-sleep-apnea indications.

  3. fdaFDA: first medication approved for obstructive sleep apnea

    FDA announcement of the Zepbound obstructive-sleep-apnea indication.

  4. clinical trialsClinicalTrials.gov: SURMOUNT-1 tirzepatide trial

    Registry record for a pivotal tirzepatide chronic-weight-management trial.

  5. pubmedSURMOUNT-1 tirzepatide randomized trial

    Peer-reviewed report of tirzepatide in adults with obesity.

How we assess sources · Suggest a correction